TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Estrella Immunopharma ( (ESLA) ) has issued an update.
On December 4, 2025, Estrella Immunopharma announced that its STARLIGHT-1 trial for the EB103 therapy has been recommended by an independent Data Safety Monitoring Board to advance to Phase II, following a favorable safety profile and a 100% complete response rate in the high-dose cohort of Phase I. This advancement marks a significant milestone for Estrella, as EB103 shows potential to address high-risk patient populations and expand access to CD19-directed cell therapies, potentially positioning the company as a leader in the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Estrella Immunopharma is a clinical-stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases. The company’s lead product candidate, EB103, utilizes ARTEMIS® technology to target CD19, a protein found on most B-cell leukemias and lymphomas.
Average Trading Volume: 276,379
Technical Sentiment Signal: Buy
Current Market Cap: $59.67M
Find detailed analytics on ESLA stock on TipRanks’ Stock Analysis page.